Lung Cancer

Panelists discuss how quality of life considerations, including prophylactic medications to prevent dermatologic toxicities and infusion-related reactions, are crucial when implementing EGFR-targeted therapies, especially the MARIPOSA regimen.

Joseph C. Murray, MD, highlights positive treatment shifts that have shaped the BRAF V600E–mutant non–small cell lung cancer treatment paradigm.

Panelists discuss how the overall survival benefit from the MARIPOSA regimen (amivantamab plus lazertinib) with a hazard ratio of 0.75 and projected survival improvement exceeding 1 year represents a significant advancement that must be weighed against toxicity concerns.

New lung cancer treatment options have emerged, and several groups are exploring treatment strategies that omit chemotherapy for locally advanced NSCLC.

In a 3-part series, Evan S. Wu, MD, PhD, will explore key issues surrounding the translatability of Chinese drug development data to a US population.

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

The DLL3- and CD3-targeted BiTE obrixtamig is being evaluated in patients with SCLC and other neuroendocrine cancers in the phase 2 DAREON-5 study.

Alexis Chidi, MD, PhD, MSPH, emphasizes the importance of having more available targeted therapies and explains NSCLC screening eligibility criteria.

The AI-driven companion diagnostic device Ventana TROP2 (EPR20043) RxDx has received FDA breakthrough device designation in NSCLC.

Alexis Chidi, MD, PhD, MSPH, details the evolution of surgical approaches in early-stage lung cancer, including wedge resections and segmentectomies.

Adjuvant aumolertinib improved disease-free survival in complete resected stage II to IIIB non–small cell lung cancer harboring EGFR mutations.

First-line adagrasib monotherapy demonstrated preliminary efficacy and tolerability in patients with SK11- and KRAS G12C–mutant NSCLC.

Early complete clearance of ctDNA was linked with clinical responses to daraxonrasib in RAS-mutant advanced non–small cell lung cancer.

First-line tiragolumab plus atezolizumab did not improve PFS and OS vs atezolizumab alone in PD-L1–high, unresectable or metastatic NSCLC.

China’s NMPA approved ivonescimab for the first-line treatment of PD-L1–positive advanced non–small cell lung cancer.

Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

A CE Mark has been granted to Optune Lua concurrent with immune checkpoint inhibitors or docetaxel for patients with metastatic non–small cell lung cancer.

Ivonescimab plus chemotherapy met the primary PFS end point vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

Fawzi F Abu Rous, MD, discusses updates to the ASCO Living Guidelines for the management of stage IV non–small cell lung cancer with driver alterations.

Panelists discuss how collaboration between pathologists, oncologists, and pulmonologists is essential for timely next-generation sequencing (NGS) testing in early-stage non–small cell lung cancer (NSCLC), emphasizing that molecular testing should ideally be ordered at diagnosis with prioritization of EGFR, ALK, ROS1, BRAF, MET, KRAS, RET, and NTRK biomarkers to guide treatment decisions before surgical intervention.

Pembrolizumab/chemotherapy was approved by Health Canada for the treatment of patients with unresectable advanced or metastatic pleural mesothelioma.

Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.

Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.